| 1 |
Rings of Continuous Functions.
Edgar R. Lorch, Leonard Gillman, Meyer Jerison · American Mathematical Monthly
|
May 1961 |
2,342 |
| 2 |
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik Kumar Ray, R. Scott Wright, David G. Kallend et al. · New England Journal of Medicine
Open access |
18 Mar 2020 |
1,652 |
| 3 |
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik Kumar Ray, Ulf Landmesser, Lawrence A. Leiter et al. · New England Journal of Medicine
Open access |
17 Mar 2017 |
1,000 |
| 4 |
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt et al. · New England Journal of Medicine
Open access |
10 Mar 2013 |
842 |
| 5 |
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick Johan Raal, David G. Kallend, Kausik Kumar Ray et al. · New England Journal of Medicine
Open access |
18 Mar 2020 |
824 |
| 6 |
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin J. Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine
Open access |
13 Nov 2016 |
773 |
| 7 |
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
Robert A. Harrington, Gregg W. Stone, Steven E. McNulty et al. · New England Journal of Medicine
Open access |
15 Nov 2009 |
626 |
| 8 |
Bivalirudin Started during Emergency Transport for Primary PCI
Philippe Gabríel Steg et al. · New England Journal of Medicine
Open access |
30 Oct 2013 |
499 |
| 9 |
Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al. · Infectious Diseases and Therapy
Open access |
30 Sep 2018 |
461 |
| 10 |
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Roger L. Nation, Jian Li, Otto Cars et al. · The Lancet Infectious Diseases
|
21 Oct 2014 |
359 |
| 11 |
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
Olga Lomovskaya, Dongxu Sun, Debora Rubio-Aparicio et al. · Antimicrobial Agents and Chemotherapy
Open access |
28 Aug 2017 |
357 |
| 12 |
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
Philippe Gabríel Steg, Deepak L. Bhatt, Christian W. Hamm et al. · The Lancet
|
3 Sep 2013 |
347 |
| 13 |
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection
Keith S. Kaye et al. · JAMA
Open access |
27 Feb 2018 |
314 |
| 14 |
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
G. Ralph Corey, Heidi Kabler, Purvi Mehra et al. · New England Journal of Medicine
Open access |
4 Jun 2014 |
310 |
| 15 |
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis
Marya D. Zilberberg, Brian Harris Nathanson, Kate Sulham et al. · BMC Infectious Diseases
Open access |
17 Apr 2017 |
231 |
| 16 |
Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study
G. Ralph Corey, Samantha Good, Hai Jiang et al. · Clinical Infectious Diseases
|
6 Oct 2014 |
224 |
| 17 |
Cardiovascular Drug Development
Christopher B. Fordyce et al. · Journal of the American College of Cardiology
Open access |
Apr 2015 |
205 |
| 18 |
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk J. Nelson, Peera Hemarajata, Dongxu Sun et al. · Antimicrobial Agents and Chemotherapy
Open access |
25 Jul 2017 |
180 |
| 19 |
ASPAN’s Evidence-Based Clinical Practice Guideline for the Promotion of Perioperative Normothermia: Second Edition
Vallire D. Hooper, Robin R. Chard, Theresa L. Clifford et al. · Journal of PeriAnesthesia Nursing
|
Dec 2010 |
177 |
| 20 |
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial
Stephen James Nicholls, Rishi Puri, Christie Mitchell Ballantyne et al. · JAMA Cardiology
Open access |
25 Jul 2018 |
173 |
| 21 |
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
Kausik Kumar Ray, Robert M. Stoekenbroek, David G. Kallend et al. · JAMA Cardiology
Open access |
25 Sep 2019 |
171 |
| 22 |
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun, Debora Rubio-Aparicio, Kirk J. Nelson et al. · Antimicrobial Agents and Chemotherapy
Open access |
17 Oct 2017 |
168 |
| 23 |
Cu-Catalyzed Decarboxylative Borylation
Jie Wang, Ming Shang, Helena Lundberg et al. · ACS Catalysis
Open access |
13 Sep 2018 |
158 |
| 24 |
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials
Dominick Joseph Angiolillo, David J. Schneider, Deepak L. Bhatt et al. · Journal of Thrombosis and Thrombolysis
|
8 May 2012 |
158 |
| 25 |
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins
Kausik Kumar Ray, Robert M. Stoekenbroek, David G. Kallend et al. · Circulation
Open access |
7 May 2018 |
156 |
| 26 |
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
R. Scott Wright, Michael G. Collins, Robert M. Stoekenbroek et al. · Mayo Clinic Proceedings
Open access |
17 Oct 2019 |
155 |
| 27 |
Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis
Marya D. Zilberberg, Brian Harris Nathanson, Kate Sulham et al. · Critical Care
Open access |
11 Jul 2016 |
137 |
| 28 |
Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: The Studying the Treatment of Acute hyperTension (STAT) Registry
Jason Neil Katz, Joel M. Gore, Alpesh J. Amin et al. · American Heart Journal
|
24 Sep 2009 |
132 |
| 29 |
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
Meredith Hackel, Olga Lomovskaya, Michael N. Dudley et al. · Antimicrobial Agents and Chemotherapy
Open access |
30 Oct 2017 |
126 |
| 30 |
Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement
George Dangas et al. · Journal of the American College of Cardiology
Open access |
23 Oct 2015 |
122 |
| 31 |
Sample Size Re-Estimation for Adaptive Sequential Design in Clinical Trials
Ping Gao, James H. Ware, Cyrus R. Mehta · Journal of Biopharmaceutical Statistics
|
7 Nov 2008 |
119 |
| 32 |
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
G. Kees Hovingh, Norman E. Lepor, David G. Kallend et al. · Circulation
Open access |
Jun 2020 |
116 |
| 33 |
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Lawrence A. Leiter, Hwee Teoh, David G. Kallend et al. · Diabetes Care
Open access |
28 Nov 2018 |
116 |
| 34 |
Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
Eric Wenzler, Mark H. Gotfried, Jeffrey S Loutit et al. · Antimicrobial Agents and Chemotherapy
Open access |
8 Sep 2015 |
115 |
| 35 |
Optimizing Trial Design
Cyrus R. Mehta, Ping Gao, Deepak L. Bhatt et al. · Circulation
|
2 Feb 2009 |
113 |
| 36 |
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Robert M. Stoekenbroek, David G. Kallend, Peter L. J. Wijngaard et al. · Future Cardiology
|
30 Oct 2018 |
109 |
| 37 |
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Philippe Généreux, Gregg W. Stone, Robert A. Harrington et al. · Journal of the American College of Cardiology
Open access |
30 Oct 2013 |
108 |
| 38 |
Medicolegal Aspects of Error in Pathology
David B. Troxel · Archives of Pathology & Laboratory Medicine
|
May 2006 |
105 |
| 39 |
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith, Janakan Krishnarajah, Philip A. Nunn et al. · British Journal of Clinical Pharmacology
Open access |
21 Jun 2017 |
105 |
| 40 |
Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure—A Pilot Study (PRONTO)
W. Frank Peacock et al. · American Heart Journal
|
15 Jan 2014 |
99 |
| 41 |
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI
Gennaro Giustino, Roxana Mehran, George Dangas et al. · Journal of the American College of Cardiology
Open access |
Oct 2017 |
95 |
| 42 |
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Harvey Douglas White, Neal S. Kleiman, Kenneth W. Mahaffey et al. · American Heart Journal
|
Dec 2006 |
95 |
| 43 |
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection
Michael Trang, Michael N. Dudley, Sujata M. Bhavnani · Current Opinion in Pharmacology
Review |
Oct 2017 |
94 |
| 44 |
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
Uwe Zeymer, Arnoud W.J. van ’t Hof, J. Adgey et al. · European Heart Journal
Open access |
21 May 2014 |
93 |
| 45 |
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
Jie Ling, Scott H. Fettner, Bert L. Lum et al. · Anti-Cancer Drugs
|
Feb 2008 |
89 |
| 46 |
Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention
Peter Clemmensen, Sebastian C. Wiberg, Arnoud W.J. van ’t Hof et al. · JACC: Cardiovascular Interventions
Open access |
2015 |
87 |
| 47 |
Kryptonite Bone Cement Prevents Pathologic Sternal Displacement
Paul W.M. Fedak, Eric Kolb, Garry W. Borsato et al. · The Annals of Thoracic Surgery
Open access |
22 Aug 2010 |
86 |
| 48 |
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
David C. Griffith, Mojgan Sabet, Ziad Tarazi et al. · Antimicrobial Agents and Chemotherapy
Open access |
20 Dec 2018 |
84 |
| 49 |
The Exacerbation of Burnout During COVID-19: A Major Concern for Nurse Safety
Jacqueline M. Ross · Journal of PeriAnesthesia Nursing
Open access |
23 Apr 2020 |
83 |
| 50 |
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser, Arash Haghikia, Lawrence A. Leiter et al. · Cardiovascular Research
|
30 Mar 2020 |
82 |